Skip to main content Skip to navigation

TEAMM

Tackling Early Morbidity and Mortality in Myeloma:

 

Assessing the benefit of antibiotic prophylaxis and it's effect on healthcare asscoiated infection

 

antibiotic.jpg

 

A randomised, multicentre, double blind, placebo-controlled trial

 

myeloma logounibhamHTACTU logo

 

TEAMM is funded by the NIHR HTA and lead by professor Mark Drayson at the University of Birmimgham in conjunction with the University of Warwick Clinical Trials Unit